- $1.94bn
- $1.69bn
- $0.24m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 7.83 | ||
Price to Tang. Book | 7.83 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 8,196.96 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -67.81% | ||
Return on Equity | -112.29% | ||
Operating Margin | -81832.91% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 0.46 | 0.25 | 1.39 | 0.6 | 0.24 | 53.08 | 251.33 | -25.97% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Directors
- John Scarlett CHM (70)
- Olivia Bloom CFO (52)
- Andrew Grethlein COO (56)
- Stephen Rosenfield EVP (70)
- Anil Kapur EVP (51)
- Melissa Kelly Behrs EVP (57)
- Edward Koval EVP
- Aleksandra Rizo EVP (46)
- Karin Eastham LED (71)
- Dawn Bir IND (50)
- V. Bryan Lawlis IND (69)
- Susan Molineaux IND (67)
- Elizabeth O'Farrell IND (56)
- Robert Spiegel IND (71)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 28th, 1990
- Public Since
- July 31st, 1996
- No. of Shareholders
- 451
- No. of Employees
- 141
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 586,912,213
- Address
- 919 East Hillsdale Boulevard, Suite 250, FOSTER CITY, 94404
- Web
- https://www.geron.com/
- Phone
- +1 6504737700
- Auditors
- Ernst & Young LLP
Upcoming Events for GERN
Geron Corp Annual Shareholders Meeting
Q2 2024 Geron Corp Earnings Release
Similar to GERN
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 18:09 UTC, shares in Geron are trading at $3.31. This share price information is delayed by 15 minutes.
Shares in Geron last closed at $3.31 and the price had moved by +45.18% over the past 365 days. In terms of relative price strength the Geron share price has outperformed the S&P500 Index by +10.14% over the past year.
The overall consensus recommendation for Geron is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Geron does not currently pay a dividend.
Geron does not currently pay a dividend.
Geron does not currently pay a dividend.
To buy shares in Geron you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.31, shares in Geron had a market capitalisation of $1.94bn.
Here are the trading details for Geron:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GERN
Based on an overall assessment of its quality, value and momentum Geron is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Geron is $5.08. That is 53.47% above the last closing price of $3.31.
Analysts covering Geron currently have a consensus Earnings Per Share (EPS) forecast of -$0.33 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Geron. Over the past six months, its share price has outperformed the S&P500 Index by +27.58%.
As of the last closing price of $3.31, shares in Geron were trading +39.92% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Geron PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Geron's management team is headed by:
- John Scarlett - CHM
- Olivia Bloom - CFO
- Andrew Grethlein - COO
- Stephen Rosenfield - EVP
- Anil Kapur - EVP
- Melissa Kelly Behrs - EVP
- Edward Koval - EVP
- Aleksandra Rizo - EVP
- Karin Eastham - LED
- Dawn Bir - IND
- V. Bryan Lawlis - IND
- Susan Molineaux - IND
- Elizabeth O'Farrell - IND
- Robert Spiegel - IND